Related Experiment Video
Updated: Jun 1, 2026
05:04
Active Probe Atomic Force Microscopy with Quattro-Parallel Cantilever Arrays for High-Throughput Large-Scale Sample Inspection
Published on: June 13, 2023
Some observations on prope tolerance.
Roy Calne1, Christopher J E Watson
1University Department of Surgery, Addenbrooke's Hospital, Cambridge, UK. calne@cam.ac.uk
Current Opinion in Organ Transplantation
|June 14, 2011
Summary
Alemtuzumab induction therapy followed by minimal immunosuppression shows a low incidence of rejection and infection in organ transplant patients. This
Area of Science:
- Transplantation immunology
- Immunosuppression strategies
Background:
- Organ transplantation requires effective immunosuppression to prevent rejection.
- Minimizing long-term immunosuppression can reduce side effects and costs.
Purpose of the Study:
- To review the rationale for using alemtuzumab induction therapy.
- To discuss the benefits of minimal maintenance immunosuppression post-transplant.
Main Methods:
- Utilizing alemtuzumab as a powerful depleting induction agent.
- Implementing a 'prope tolerance' protocol with reduced maintenance immunosuppression.
Main Results:
- Confirmed low rates of rejection, infection, and post-transplant lymphoproliferative disorder (PTLD).
- Positive outcomes observed in African-American recipients.
- Treg cells implicated in graft acceptance; reduced transplantation costs noted.
Conclusions:
- The alemtuzumab induction and minimal maintenance immunosuppression protocol is effective and well-tolerated.
- This approach offers a favorable safety profile and reduced costs.
- Minimal maintenance immunosuppression is considered the optimal current therapy for organ transplant patients.
